WARREN, N.J., Oct. 16, 2012 (GLOBE NEWSWIRE) -- MonoSol Rx, LLC (“MonoSol Rx”), the developer of PharmFilm® drug delivery technology, announced today that challenges brought by MonoSol Rx competitor, BioDelivery Sciences International, Inc. (Nasdaq:BDSI) (“BDSI”), have been soundly defeated. MonoSol Rx’s PharmFilm® patents (U.S. Patent No. 7,425,292 (“the ‘292 patent”) and U.S. Patent No. 7,357,891 (“the ‘891 patent”), emerged from reexamination at the U.S. Patent and Trademark Office (“PTO”) stronger than they entered, each enhanced with multiple new claims.
